Bold truth: families shouldn’t have to mortgage their future to save a child’s life. Yet that’s the reality for a Guernsey family who’ve sold belongings to cover their nine-month-old’s essential medicine. But here’s where it gets controversial: the price tag is astronomical, and the local system isn’t funding this critical treatment.
The mother, Kiely Luscombe, and her partner say they feel abandoned after learning Arnold’s medication will cost £312.70 per bottle—which lasts about a month—because it isn’t funded on Guernsey prescriptions. “I just feel lost,” Luscombe says. “My partner and I have tried so much, and we’re at the end of the road.”
Teena Bhogal, Chief Pharmacist, emphasizes the help available: clinicians can contact the Prescribing Support Unit (PSU) for advice and to explore alternatives, or to consider adding a medication to the prescribing list where appropriate. Bhogal notes that the PSU hasn’t yet received requests for this specific drug, and urges clinicians facing similar situations to reach out.
Arnold had a turbulent start, with vomiting and stomach pains from just three weeks old, leading to a November 2025 transfer to Southampton Hospital. He’s been diagnosed with a digestive disorder—dysmotility and hypermotility—that makes it hard for him to keep food down and to have regular bowel movements. Luscombe recalls the severity: “He had to be held 24-7 because he was in so much pain. His tummy was tight and it hurt; he was arching his back constantly.”
At Southampton General, Arnold was prescribed Mebeverine, but the relief was temporary. Upon returning to Guernsey, the dosage had to be increased as the supply dwindled, and the family discovered the monthly cost would keep rising. Initially, they managed a reduced first price of £205.50, but continuing monthly costs now total £312.70. Arnold must take the oral solution form, intended for children aged three and older, which isn’t funded by the States of Guernsey.
Luscombe points out the financial strain: “We’re looking at one bottle a month, about £3,500 a year. We’ve got four children between us, so this isn’t feasible.” Doctors reportedly suggested stretching a bottle’s life by reducing doses, but Arnold’s condition worsened. Luscombe describes alarming symptoms: a swollen abdomen, vomiting, constipation, and a loss of quality of life.
Her frustration is palpable: “I don’t understand why it should cost so much money just to give him that quality of life.” While Arnold’s father has returned to work, Luscombe remains the full-time caregiver. She hopes for disability support in the future, but anticipates months of waiting—and with that, ongoing uncertainty about how to sustain Arnold’s care.
This story underscores a bigger question: when lifesaving medication isn’t funded locally, who picks up the bill—and what happens to families caught in the gap? If you have thoughts on drug funding, access to pediatric care, or what systems can do to prevent families from hitting brick walls, share them in the comments. Do you think health services should guarantee access to essential medicines, regardless of funding status, or should there be broader safety nets to prevent families from facing impossible choices?
